

Adakveo® (crizanlizumab-tmca)

When requesting Adakveo® (crizanlizumab-tmca), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Adakveo is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Coverage Guidelines

Sickle cell disease (SCD)

- An individual is 16 years of age or older
- Adakveo is prescribed by or in consultation with a physician who specializes in the treatment of sickle cell disease (e.g., a hematologist)

Approval duration: 12 months

Dosing Recommendation

The recommended Adakveo dose is 5 mg/kg administered by intravenous infusion over a period of 30 minutes on week 0, week 2, and every 4 weeks thereafter.

References

1. Adakveo® injection for intravenous use [prescribing information]. East Hanover, NJ: Novartis; November 2019.
2. Piel FB, Steinberg MH. Sickle cell disease. *N Engl J Med*. 2017;376:1561-1573.
3. The National Institutes of Health – National Heart, Lung, and Blood Institute Evidence-Based Management of Sickle Cell Disease, Expert Panel Report 2014. Available at: <http://www.nhlbi.nih.gov/guidelines>. Accessed on November 18, 2019.